The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 26, 2023
Filed:
Dec. 30, 2020
Applicant:
Biolamina Ab, Sundbyberg, SE;
Inventors:
Outi Hovatta, Esbo, FI;
Karl Tryggvason, Singapore, SG;
Assignee:
BioLamina AB, Sundbyberg, SE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/079 (2010.01); C12N 5/00 (2006.01); A61K 9/00 (2006.01); A61K 35/30 (2015.01);
U.S. Cl.
CPC ...
C12N 5/0621 (2013.01); A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 35/30 (2013.01); C12N 5/0056 (2013.01); C12N 2500/92 (2013.01); C12N 2500/98 (2013.01); C12N 2501/115 (2013.01); C12N 2506/02 (2013.01); C12N 2533/50 (2013.01); C12N 2533/52 (2013.01);
Abstract
The present disclosure relates to the use of laminin-521 in obtaining retinal pigment epithelium (RPE) cells. Pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in totally defined and xeno-free conditions. A first cell culture medium contains a growth factor, and a second cell culture medium does not contain growth factor. The stem cells are first exposed to the first cell culture medium, then exposed to the second cell culture medium for a longer time period. After a number of weeks, clinical grade RPE cells are obtained from the stem cells.